| Bioactivity | Keap1-Nrf2-IN-20 (Compound ZC9) is an inhibitor for Keap-Nrf2 pathway with KD2 of 51 nM. Keap1-Nrf2-IN-20 exhibits good cell permeability, cell activity, and metabolic stability (serum t1/2 > 24 h)[1]. |
| Invitro | Keap1-Nrf2-IN-20 (15-60 μM) 抑制 TNF-α 和 IL-6 在 LPS (HY-D1056) 诱导的小鼠腹腔巨噬细胞炎症中的表达，具有抗炎活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Keap1-Nrf2-IN-20 相关抗体: |
| In Vivo | Keap1-Nrf2-IN-20 (20-80 mg/kg，尾静脉注射，单剂量) 可减轻 C57BL/6 小鼠模型中 LPS 诱导的急性肺损伤[1]。Keap1-Nrf2-IN-20 (56 mg/kg，静脉注射，单剂量) 在 Sprague Dawley 大鼠中表现出令人满意的药代动力学特征，半衰期 (T1/2)、清除率 (CL) 、曲线下面积（AUC）和表观分布容积（V）分别为 0.22 h，3.90 L/h/kg，14344.57 h·ng/mL 和 1.26 L/kg[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Formula | C42H67N11O19 |
| Molar Mass | 1030.04 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zou J, et al., Cyclic Peptide Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Design, Synthesis, and In Vivo Treatment of Acute Lung Injury. J Med Chem. 2024 Mar 28;67(6):4889-4903. |